Vifor Pharma AG (LTS:0RPD) EV-to-EBIT : 32.35 (As of Apr. 27, 2024)

Vifor Pharma AG EV-to-EBIT Chart

Vifor Pharma AG Annual Data
	Trend	Dec12	Dec13	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21
EV-to-EBIT		Get a 7-Day Free Trial					50.61	30.14	38.96	34.88	32.65

Vifor Pharma AG Semi-Annual Data
	Jun12	Dec12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21
EV-to-EBIT	Get a 7-Day Free Trial															38.96	-	34.88	-	32.65

Competitive Comparison of Vifor Pharma AG's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Vifor Pharma AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vifor Pharma AG's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vifor Pharma AG's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Vifor Pharma AG's EV-to-EBIT falls into.

Vifor Pharma AG EV-to-EBIT Calculation

Vifor Pharma AG's EV-to-EBIT for today is calculated as:

Vifor Pharma AG's current Enterprise Value is CHF10,375 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Vifor Pharma AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2021 was CHF321 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vifor Pharma AG  (LTS:0RPD) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Vifor Pharma AG's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2021 is calculated as:

Vifor Pharma AG's Enterprise Value for the quarter that ended in Dec. 2021 was CHF10,650 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Vifor Pharma AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2021 was CHF321 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vifor Pharma AG EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Vifor Pharma AG's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Vifor Pharma AG (LTS:0RPD) Business Description